Merck & Co
Merck and Roche extend Victrelis co-promotion deal to Europe
July 22, 2011Sales and Marketing Merck & Co, Roche, Victrelis, hepatitis C
Merck & Co is ramping up efforts to push its new hepatitis C treatment Victrelis to the fore, signing a …
Merck to close one facility, boosts another
July 5, 2011Manufacturing and Production, Research and Development Ireland, Merck & Co, pharma job cuts, pharma manufacturing news
Merck & Co continues to shake up its network of facilities, deciding to close a recently-acquired site in the USA …
Merck to develop biosimilar of Pfizer’s Enbrel
June 15, 2011Research and Development, Sales and Marketing Enbrel, Merck & Co, biosimilar
Merck & Co is to develop its own version of Pfizer’s ageing arthritis drug Enbrel with a South Korean manufacturer. …
Merck redesigns drug labels for clarity
June 14, 2011Manufacturing and Production FDA, Labelling, Merck & Co
The FDA has approved a major overhaul of labelling for a range of Merck & Co products, paving the way …
Merck plans cancer drug submissions later this year
June 7, 2011Research and Development, Sales and Marketing Merck & Co, ridaforolimus
Merck & Co is to submit its oral investigational cancer drug ridaforolimus to European and US regulators later this year …
GSK and Merck cut vaccine prices
June 6, 2011Sales and Marketing Bill and Melinda Gates Foundation, GSK, Merck & Co, developing world, vaccines
GlaxoSmithKline and Merck & Co have pledged to offer their rotavirus vaccines at discounted prices to developing countries. GSK is …
Merck’s hepatitis drug Victrelis approved by FDA
May 16, 2011Sales and Marketing Merck & Co, Victrelis, boceprevir, hepatitis C
The FDA has approved Merck’s hepatitis C drug Victrelis, the first oral treatment for the disease. Victrelis (boceprevir) has been …
Merck & Co kicks off expansion of Durham vaccines facility
April 26, 2011Manufacturing and Production Merck & Co, manufacturing and production, vaccines
Merck & Co is expanding its vaccines facility in North Carolina, USA, bucking a recent trend at the manufacturer for …
J&J and Merck reach compromise on arthritis drug rights
April 19, 2011Sales and Marketing Johnson & Johnson, Merck & Co, Remicade, Simponi
Johnson & Johnson and Merck & Co have agreed to split the regional rights to arthritis drugs Remicade and Simponi …
Merck says sale of Oss facility would be too expensive
March 8, 2011Manufacturing and Production, Research and Development Holland, Merck & Co, Oss, Oss pharma research, Pantarhei Bioscience
The debate around the closure of Merck & Co’s R&D and manufacturing unit in Oss, the Netherlands, rumbles on, with …
Fujifilm buys into bio with Merck acquisitions
March 2, 2011Manufacturing and Production Biomanufacturing, Fujifilm, Merck, Merck & Co, Merck/MSD Biomanufacturing Network, contract manufacturing
Japanese photography and imaging company Fujifilm continued its diversification into other sectors with the acquisition of the Merck/MSD Biomanufacturing Network, …
Sale of Organon facility in Oss may avert closure
February 15, 2011Manufacturing and Production Merck & Co, Netherlands, Oss
The fate of an Organon manufacturing and R&D facility in the Netherlands, currently under threat of closure by parent company …
Merck dipped into the red as 2010 ended
February 4, 2011Sales and Marketing 2010 pharma results, Merck & Co
Merck & Co made a $531 million loss in the final quarter of 2010 – down from a profit of …
Bio and clinical plants feature in 2011 FOYA honours
January 25, 2011Manufacturing and Production MedImmune, Merck & Co, Novartis, Pfizer, Roche, Shire HGT, pharma manufacturing
Three US and three European manufacturing plants have been shortlisted for the annual Facility of the Year awards, with the …
Merck suffers late-stage blow to vorapaxar
January 18, 2011Research and Development ACS, Merck & Co, acute coronary syndrome, anticoagulant, heart attack, peripheral arterial disease, stroke, vorapaxar
An increased risk of bleeding caused by pipeline drug vorapaxar has dealt Merck a major blow.The Data and Safety Monitoring …
Latest content
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions
